Roche Diversifies With $105m-Plus Adheron Buy
This article was originally published in Scrip
Roche will pay $105m up front and up to $475m in milestone fees to acquire Adheron Therapeutics in a deal that may help expand the Swiss big pharma portfolio in the company's key therapeutic areas outside of oncology.
You may also be interested in...
Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
The cancer drug developer was planning to go public later this year, but its series B investor Boxer Capital proposed a merger with its special purpose acquisition corporation, BCTG Acquisition.